A Mathematical Model of Cytomegalovirus (CMV) Infection in Transplant Patients Grace M. Kepler Center for Research in Scientific Computation North Carolina.

Slides:



Advertisements
Similar presentations
ID Week, Philadelphia October Clinically Applied Variation in Replication Kinetics During Episodes of Post-Transplant Cytomegalovirus (CMV) Infections.
Advertisements

Herpesviruses Herpes simplex I & II (cold sores, genital herpes)
Dengue Transfusion Risk Model Lyle R. Petersen, MD, MPH Brad Biggerstaff, PhD Division of Vector-Borne Diseases Centers for Disease Control and Prevention.
POLYOMAVIRUS INFECTION IN RENAL ALLOGRAFTS: PROGRESS SINCE BANFF 1999 Parmjeet Randhawa Associate Professor Division of Transplantation Pathology Department.
HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,
Stochastic Stage-structured Modeling of the Adaptive Immune System Dennis L. Chao 1, Miles P. Davenport 2, Stephanie Forrest 1, and Alan S. Perelson 3.
Verify or refute the use of Non Linear Mixed Effect Model for Interferon effect on HCV Hila David Shimrit Vashdi Project Advisors: Prof. Avidan Neumann.
System Science Ph.D. Program Oregon Health & Science Univ. Complex Systems Laboratory 1 A Tale of Two Methods—Agent-based Simulation and System Dynamics—
1 Pathogenic Viruses Name of virus; what family it belongs to; what disease it causes. –DNA or RNA? Ss or ds? –Characteristics of disease, symptoms. –Viral.
Micro 615 Principals of Virology: Virus Structure, Classification, Detection & Persistence Alice Telesnitsky.
SAMPLING DISTRIBUTIONS. SAMPLING VARIABILITY
Chapter 7: Variation in repeated samples – Sampling distributions
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
DR.MOHAMMED ARIF ASSOCIATE PROFESSOR CONSULTANT VIROLOGIST HEAD OF THE VIROLOGY UNIT Cytomegalovirus (CMV)
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases Centers.
Lara Isobel Compston, Daniel Candotti, Jean-Pierre Allain
Optimizing CMV Prevention Sharon F. Chen, MD, MS Hayley Gans, MD February 19, 2015.
HIV Organ Policy Equity (HOPE) Act Research Criteria: follow-up discussion Advisory Committee on Organ Transplantation April 13, 2015.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
Viral Hepatitis Australian Family Physician Vol. 30 No.5, May 2001 Presented by 郭詠怡 Date presented:25/8/2003.
Estimation of Statistical Parameters
Clinical Care of HIV, AIDS and Opportunistic Infections
The Tale of two Herpes Viruses: CMV and EBV Sharon F. Chen, M.D., M.S. Hayley Gans, M.D. Pediatric Infectious Diseases Pediatric Infectious Diseases Program.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Common viral infections HERPES VIRUS INFECTIONS The objectives of this lecture:  To know the clinically important HVs.  To know the common characteristics.
CMV (Cytomegalovirus) reactivation and immunosupression in allogeneic transplantation Marie Waller Bone Marrow Transplant Coordinator Manchester Royal.
1 Modelling the interactions between HIV and the immune system in hmans R. Ouifki and D. Mbabazi 10/21/2015AIMS.
1 30/11/98 Herpes Viruses Cytomegalovirus. 2 30/11/98 Presentation Outline  Structure  Classification  Multiplication  Clinical manifestations  Epidemiology.
This presentation is made available through a Creative Commons Attribution- Noncommercial license. Details of the license and permitted uses are available.
Risk Assessments: Models for Estimating the Risk of Transmitting TSE by Human Tissue Intended for Transplantation Rolf E. Taffs, Ph.D. Center for Biologics.
National Institute for Biological Standards and Control Assuring the quality of biological medicines Human Cytomegalovirus (HCMV) Proposed 1 st International.
1 An Interim Monitoring Approach for a Small Sample Size Incidence Density Problem By: Shane Rosanbalm Co-author: Dennis Wallace.
Arnold School of Public Health Health Services, Policy, and Management 1 Drug Treatment Disparities Among African Americans Living with HIV/AIDS Carleen.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Copyright  2003 by Dr. Gallimore, Wright State University Department of Biomedical, Industrial Engineering & Human Factors Engineering Human Factors Research.
Effect of antiviral use on the emergence of resistance to nucleoside analogs in Herpes Simplex Virus, Type 1 Marc Lipsitch, Bruce Levin, Rustom Antia,
PhD We knew nothing about the set-point viral loads. What was unknown about HIV-1 infection before this paper was published in 2007? 1.Virus density.
DR.MOHAMMED ARIF ASSOCIATE PROFESSOR CONSULTANT VIROLOGIST HEAD OF THE VIROLOGY UNIT Cytomegalovirus (CMV)
Viruses DNA viruses: 6 families Poxviridae Herpesviridae Adenoviridae Hepadnaviridae Papovaviridae Parvoviridae.
Transplantation in HIV Michelle Roland, MD Assistant Professor of Medicine UCSF Positive Health Program at SFGH.
An audit of CMV disease in renal transplant recipients transplanted at the Queen Elizabeth Hospital Birmingham Gemma Banham, Shazia Shabir, Richard Borrows.
Responses to FDA Gene Therapy Letter : Adenovirus Vector Titer Measurements and RCA Levels BRMAC July 13, 2001 Steven R. Bauer, Ph.D Division of Cellular.
Transplantation Immunology Unit College of Medicine
Risk assessment: The Safety of Blood Products presented by Dr. Thomas R. Kreil Baxter BioScience on behalf of the PPTA Pathogen Safety Steering Committee.
Transplantation Prof. Zahid Shakoor College of Medicine King Saud University.
Pathogenicity of Infectious Diseases. PATHOGENENVIRONMENT HOST DISEASE TRIAD Host-Parasite Interactions OTHER MICROBES Microbial Interactions.
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
United States Organ Transplantation SRTR & OPTN Annual Data Report, 2011 Kidney.
Margaret L. Green, Wendy M. Leisenring, Hu Xie, Roland B. Walter, Marco Mielcarek, Brenda M. Sandmaier, Stanley R. Riddell and Michael Boeckh Blood NUM.
Chapter 9: Means and Proportions as Random Variables 9.1 Understanding dissimilarity among samples 9.2 Sampling distributions for sample proportions 9.3.
Infection following KTP 신장내과 R3 김경엽. Infections Infections Leading cause of morbidity and mortality in the early posttransplant period Leading cause of.
Question 1 A new test to diagnose urinary tract infections (UTIs) is being evaluated. The sensitivity of the test is 70% and the specificity is 90%. In.
IMMUNODEFICIENCIES HIV2 324 PHT Dr. Sarah I. Bukhari PhD in Clinical Microbiology Department of Pharmaceutics Office: rd floor
Human Cytomegalovirus (HCMV)
Case Two: When the drugs don’t work Drug resistance in CMV
XENOTRANSPLANTATION The transplantation of an organ or
John P. Dickerson, Tuomas Sandholm In AAAI, 2015
Relationship between CMV & PU disease
Number of transplants, by donor type figure 8.1
Transplantation Immunology Unit College of Medicine
Figure 1. Study participant flowchart
PHARMACOTHERAPY III PHCY 510
Hiv.
Active Immunization Active immunity develops naturally in response to an infection. It can also develop following/ from immunization, also called vaccination.
Sampling Distribution
Sampling Distribution
Epidemiological Modeling to Guide Efficacy Study Design Evaluating Vaccines to Prevent Emerging Diseases An Vandebosch, PhD Joint Statistical meetings,
Measures of Morbidity.
Longitudinal Analysis Beyond effect size
Human Herpes Virus 6 Plasma DNA Positivity after Hematopoietic Stem Cell Transplantation in Children: an Important Risk Factor for Clinical Outcome  P.J.
Presentation transcript:

A Mathematical Model of Cytomegalovirus (CMV) Infection in Transplant Patients Grace M. Kepler Center for Research in Scientific Computation North Carolina State University

Outline Significance Modeling goals Mathematical/Biological model Parameter approximation Numerical results Conclusions

Transplantation Numbers (UNOS, 2005) More than 27,000 organs transplanted Approximately 90,000 waiting for organs 153,000 living with functioning organ transplant The number of individuals waiting for, receiving, or living with a transplanted organ(s) is significant.

Life-long immunosuppression is the standard of care for transplant patients. Common pathogens (eg., influenza) Opportunistic infections (eg., Listeria) Latent infections (eg., HCV, VZV, CMV) Immunocompromised individuals are susceptible to infections from

CMV infection Most significant threat to patient and graft health Directly or indirectly causes: –allograft rejection –decreased graft and patient survival –predisposition to opportunistic infections and malignancies

Facts about CMV A herpes virus 50-90% of adults are infected (geographic variation) Primary infection in immunocompetent individuals is generally asymptomatic (some get mononucleosis-like illness ) Establishes lifelong latent infection Latent infection is well control by healthy immune systems Reactivation rare in healthy individuals

CMV Infection Risk In Transplantation DonorRecipientType D+R-primary D-R+reactivation D+R+superinfection D-R-risk with exposure

Optimal care of individuals with transplanted organs is important No universal agreement among transplant centers about –Prophylactic vs. preemptive antiviral treatment –Optimal duration of antiviral treatment Optimal treament may vary among subpopulations (eg., D+ R- vs D- R+)

Modeling goals Create a within-patient dynamic model of CMV infection Describe dynamics of cell and viral populations with ODEs

Modeling goals Individualized medicine –model equations are the same for each individual –model parameter values may vary among individuals –individuals are characterized by their particular set of parameter values –parameter values for each individual determine their particular infection dynamics –allowing prediction for each individual

Longitudinal data Viral load data for one individual. Censored data

Parameter estimation Estimate model parameters from the data.

Prediction Use the model and characterstic parameters to predict infection dynamics.

Modeling goal – Population predictions Estimate characteristic parameters for many individuals using longitudinal data

Modeling goal – Population predictions Create a probabilistic model to describe parameter distributions

Modeling goal – Population predictions Use the probabilistic model to create virtual patients Predict population behavior (eg., treatment regimens) Antiviral treatment

Modeling goal – Population predictions Use a stochastic model to sample the parameter distributions (virtual patients) Predict population behavior (eg., treatment regimens) Antiviral treatment

Modeling goal – Population predictions Use a stochastic model to sample the parameter distributions (virtual patients) Predict population behavior (eg., treatment regimens) Antiviral treatment

Modeling considerations Start simply, capture most salient biological features –a model that can describe primary, latent, and reactivated infections in healthy or immunocompromised individuals Use clinical measurements to inform the model Model cell and viral populations in the blood

Math/Bio model - virions VIRIONS (free virus)

Math/Bio model – susceptible cells SUSCEPTIBLE CELLS (monocytes) cell replication and death

ACTIVELY - INFECTED CELLS Math/Bio model - actively-infected cells

Math/Bio model – viral-induce cell lysis

Math/Bio model – immune response CMV-SPECIFIC IMMUNE EFFECTOR CELLS

Math/Bio model – immune suppression

Math/Bio model – lysing of infected cells

LATENTLY- INFECTED CELLS Math/Bio model – latently-infected cells

Math/Bio model – reactivation reactivation of monocytes upon differentiation

Math/Bio model – cell replication/death

State Variables VariableDescriptionUnits Vvirions virions/  L-blood Evirus-specific immune effector cells cells/  L-blood RIRI actively-infected cells cells/  L-blood RSRS susceptible cells cells/  L-blood RLRL latently-infected cells cells/  L-blood

Mathematical equations

Clinical data Real-time quantitave PCR measurements of viral DNA in plasma ( ) Antigenemia assay ( ) PBMC depleted ELISPOT assay ( ) Longitudinal measurements

Statistical framework Intra-subject variation of observations –assay errors –physiological fluctuations –assay limits (cesored data)

Parameter approximations Physiological information Experimental measurements Auxilliary parameters Using reduced models for specific time regimes Unknown parameters Viral load decay Emery1999

Parameter approximations Provide initial values for parameter estimation when data is available Allow exploratory simulations of model behavior

Immunocompetent Primary infection Initial conditions:

Immunocompetent The latent infection state is characterized by the equilibrium levels of the state variables following primary infection. Latent infection

Immunosuppression Primary infection

Immunosuppression Primary infection

Immunosuppression Primary infection

Immunosuppression - Latency

D-R+ Transplant Scenario The donor tissue has no CMV virions or latently-infected cells (D-) Prior to transplantation, recipient has a latent CMV infection, characterized by low levels of V, R I, and R L that is controlled by the immune effector cells E After transplantation, pharmacolgical immunosuppression can result in a secondary (reactivated) CMV infection

Reactivation Immune suppression of an individual with a latent CMV infection

Conclusion Created a mathematical model for CMV infection in both immunocompetent and immunocompromised individuals Identified data that can be collected to inform the model Approximated values for most of the model parameters Model exhibits primary, latent, and secondary (reactivated) infections Latent infection is characterized by low-level viral load and actively-infected cells Simulation of reactivated infection approximates CMV infection in D-R+ transplant patients

CMV infection in other immunocompromised individuals Most common congenital infection –can result in developmental and sensory disabilites Retinitis infection in AIDS patients. CMV CTL-inflation may be a cause of immunosuppression in elderly individuals

Challenges Get data –parameter estimation –predictive capability Further model development –other transplant situations (eg., D+R-) –HLA type, antiviral treatment,...

Collaborators Tom Banks, CRSC, NCSU Marie Davidian, CQSB, NCSU Eric Rosenberg, MGH, Harvard